If you are visually impaired or blind, you can visit the PDF version by Pressing CONTROL + ALT + 4
<br /> DERMATOLOGY<br /> Review • emjreviews.com<br /> Reviews of the Psoriasis<br /> Treatment Landscape<br /> Contents<br /> Previously published content from<br /> EMJ Dermatology Supplements.<br /> + SPIN 2019<br /> IL-23 Inhibition as a Key Component in Psoriasis Treatment is 3<br /> Here to Stay<br /> + WCD 2019<br /> IL-23 Inhibition in Psoriasis: A Novel Approach to Convenient, 11<br /> Consistent Clearance<br /> + ESDR 2019<br /> Pathways to Silencing Psoriasis: Remission or Cure? 21<br /> + EADV 2019<br /> IL-23 Inhibition: From Pathophysiological Jungle to Clinical Clearance 28<br /> Latest Highlights from Guselkumab in Psoriasis from EADV 2019 36<br /> Cover Images © Iakov Kalinin, Sergey Dzyuba, eonaya, Sean Pavone / 123RF.com<br /> 2<br /> DERMATOL SUPPL • December 2019 <a title="EMJ Dermatology Review 2019 page 1" href="http://viewer.zmags.com/publication/00496323?page=1"> DERMATOLOGY Review • emjreviews.com </a> <a title="EMJ Dermatology Review 2019 page 2" href="http://viewer.zmags.com/publication/00496323?page=2"> Contents Previously published content from EMJ D</a> <a title="EMJ Dermatology Review 2019 page 3" href="http://viewer.zmags.com/publication/00496323?page=3"> IL-23 Inhibition as a Key Component in Psorias</a> <a title="EMJ Dermatology Review 2019 page 4" href="http://viewer.zmags.com/publication/00496323?page=4"> He explored VOYAGE 1 data that showed that the IL</a> <a title="EMJ Dermatology Review 2019 page 5" href="http://viewer.zmags.com/publication/00496323?page=5"> show switching between biologics is safe and effe</a> <a title="EMJ Dermatology Review 2019 page 6" href="http://viewer.zmags.com/publication/00496323?page=6"> treated, with updosing effective in some patients</a> <a title="EMJ Dermatology Review 2019 page 7" href="http://viewer.zmags.com/publication/00496323?page=7"> In the reSURFACE 1 trial data for tildrakizumab (</a> <a title="EMJ Dermatology Review 2019 page 8" href="http://viewer.zmags.com/publication/00496323?page=8"> improvements in scalp scores versus 69.2% re</a> <a title="EMJ Dermatology Review 2019 page 9" href="http://viewer.zmags.com/publication/00496323?page=9"> age, sex, and comorbidities from registries to in</a> <a title="EMJ Dermatology Review 2019 page 10" href="http://viewer.zmags.com/publication/00496323?page=10"> VOYAGE 1 trial. J Am Acad Dermatol. 31. 2017</a> <a title="EMJ Dermatology Review 2019 page 11" href="http://viewer.zmags.com/publication/00496323?page=11"> IL-23 Inhibition in Psoriasis: A Novel Approach </a> <a title="EMJ Dermatology Review 2019 page 12" href="http://viewer.zmags.com/publication/00496323?page=12"> and IMMvent for risankizumab. Taken together, the</a> <a title="EMJ Dermatology Review 2019 page 13" href="http://viewer.zmags.com/publication/00496323?page=13"> leads to exacerbation of IBD. This unexpected cli</a> <a title="EMJ Dermatology Review 2019 page 14" href="http://viewer.zmags.com/publication/00496323?page=14"> Patients responding to guselkumab at Week 20 were</a> <a title="EMJ Dermatology Review 2019 page 15" href="http://viewer.zmags.com/publication/00496323?page=15"> PASI 75 response. By Week 28, 74% patients on eit</a> <a title="EMJ Dermatology Review 2019 page 16" href="http://viewer.zmags.com/publication/00496323?page=16"> Patient Profiling in Daily Practice: Which Drug </a> <a title="EMJ Dermatology Review 2019 page 17" href="http://viewer.zmags.com/publication/00496323?page=17"> Table 1: Treatment choices in psoriasis with como</a> <a title="EMJ Dermatology Review 2019 page 18" href="http://viewer.zmags.com/publication/00496323?page=18"> of HBV infections, whereas HBV reactivation has b</a> <a title="EMJ Dermatology Review 2019 page 19" href="http://viewer.zmags.com/publication/00496323?page=19"> taltz-epar-product- information_ en.pdf. Last acc</a> <a title="EMJ Dermatology Review 2019 page 20" href="http://viewer.zmags.com/publication/00496323?page=20"> 40. Yiu ZZN et al. Risk of serious infec</a> <a title="EMJ Dermatology Review 2019 page 21" href="http://viewer.zmags.com/publication/00496323?page=21"> Pathways to Silencing Psoriasis: Remission or Cur</a> <a title="EMJ Dermatology Review 2019 page 22" href="http://viewer.zmags.com/publication/00496323?page=22"> Reducing treatment burden for patients, and the p</a> <a title="EMJ Dermatology Review 2019 page 23" href="http://viewer.zmags.com/publication/00496323?page=23"> CVrrisiskffacttorrs Obesity CVD Diabetes Dyslip</a> <a title="EMJ Dermatology Review 2019 page 24" href="http://viewer.zmags.com/publication/00496323?page=24"> psychosocial and lifestyle-associated factors to </a> <a title="EMJ Dermatology Review 2019 page 25" href="http://viewer.zmags.com/publication/00496323?page=25"> 5.0 concentration (pg/mL) 2.5 Log 2 0 Lower </a> <a title="EMJ Dermatology Review 2019 page 26" href="http://viewer.zmags.com/publication/00496323?page=26"> common pathways and complex relationships among i</a> <a title="EMJ Dermatology Review 2019 page 27" href="http://viewer.zmags.com/publication/00496323?page=27"> biosimilars for moderate-to-severe 48. p</a> <a title="EMJ Dermatology Review 2019 page 28" href="http://viewer.zmags.com/publication/00496323?page=28"> IL-23 Inhibition: From Pathophysiological </a> <a title="EMJ Dermatology Review 2019 page 29" href="http://viewer.zmags.com/publication/00496323?page=29"> arthritis (PsA) disease domains, and these differ</a> <a title="EMJ Dermatology Review 2019 page 30" href="http://viewer.zmags.com/publication/00496323?page=30"> TNF-α IL-17A/F IL-23 IL-17C/E Figure 1: </a> <a title="EMJ Dermatology Review 2019 page 31" href="http://viewer.zmags.com/publication/00496323?page=31"> EMA Guselkumab November 2017 2017 </a> <a title="EMJ Dermatology Review 2019 page 32" href="http://viewer.zmags.com/publication/00496323?page=32"> But how does the efficacy of IL-23 inhibitors com</a> <a title="EMJ Dermatology Review 2019 page 33" href="http://viewer.zmags.com/publication/00496323?page=33"> Therefore, dermatologists play a key role in the </a> <a title="EMJ Dermatology Review 2019 page 34" href="http://viewer.zmags.com/publication/00496323?page=34"> psoriasis. J Allergy Clin Immunol. 2017;139(3):92</a> <a title="EMJ Dermatology Review 2019 page 35" href="http://viewer.zmags.com/publication/00496323?page=35"> arthritis. Clin Cosmet Investig Dermatol. 2015;8:</a> <a title="EMJ Dermatology Review 2019 page 36" href="http://viewer.zmags.com/publication/00496323?page=36"> Latest Highlights from Guselkumab in Psoriasis </a> <a title="EMJ Dermatology Review 2019 page 37" href="http://viewer.zmags.com/publication/00496323?page=37"> clinical trial programme in psoriasis, as present</a> <a title="EMJ Dermatology Review 2019 page 38" href="http://viewer.zmags.com/publication/00496323?page=38"> scores at Week 48 compared with those who receive</a> <a title="EMJ Dermatology Review 2019 page 39" href="http://viewer.zmags.com/publication/00496323?page=39"> achieved IGA 0 regardless of psoriasis treatment </a> <a title="EMJ Dermatology Review 2019 page 40" href="http://viewer.zmags.com/publication/00496323?page=40"> Differential Impact of IL-23 vs IL-1</a> <a title="EMJ Dermatology Review 2019 page 41" href="http://viewer.zmags.com/publication/00496323?page=41"> with guselkumab, while the equivalent cellular po</a> <a title="EMJ Dermatology Review 2019 page 42" href="http://viewer.zmags.com/publication/00496323?page=42"> and tolerability profile of this IL-23 inhib</a>